Zevra Therapeutics Refiles Arimoclomol Application With FDA
By Colin Kellaher
Zevra Therapeutics has resubmitted a new drug application seeking U.S. Food and Drug Administration approval of its lead product candidate arimoclomol for Niemann-Pick disease type C, a rare neurodegenerative disorder.
Zevra on Wednesday said it expects an acknowledgment letter from the FDA that the resubmission is complete and setting a target action date within 30 days.
The Celebration, Fla., company said it expects the FDA to classify the resubmission as Class II, making it subject to a review period by the agency within six months from the date of submission.
Denmark's Orphazyme, which previously owned the arimoclomol program, initially filed for FDA approval of the drug in September 2020.
However, the FDA in June 2021 issued a so-called complete response letter, indicating that it wouldn't approve the application in its current form and calling for additional qualitative and quantitative evidence.
Zevra, which acquired all of the assets and operations of Orphazyme related to arimoclomol in May 2022, said it believes it has addressed the issues the FDA raised in the complete response letter, and that it is accelerating launch preparations in anticipation of an FDA approval.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 27, 2023 08:09 ET (13:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks